Latest news for PureTech Health (OTC:PTCHF) Stock

PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological & neuropsychological disorders, among others. It operates in the following segments: Wholly-Owned Programs, Controlled Founded Entities, and Parent Companies & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept and focused on some of society's healthcare needs.

PURETECH HEALTH PLC ORD by PureTech Health PLC

PureTech Health PLC

PureTech Health plc (PRTC) Q4 2023 Earnings Call Transcript

PureTech Health plc (PRTC) Q2 2024 Earnings Call Transcript

5 Reasons Bristol-Myers Squibb Looks Good Now (Rating Upgrade)

BMYMP

PRTC

PTCHF

RPRX

PureTech Health

News

Intraday Update

Markets

Movers

Trading Ideas

AACAF

AACAY

AAGIY

AAIGF

AAMMF

AAUKF

AAVMY

AAVVF

ABBRF

ABCP

ABILF

ABMC

ABNAF

ABSSF

ACDVF

ACGBY

ACHFF

ACKRF

ACNDF

ACNNF

ACOPF

ACRL

ACSAY

ACUIF

ADAD

ADDDF

ADDYY

ADMT

ADYEY

AEGOF

AERG

AETUF

AEXAY

AFLYY

AGCBF

AGESY

AGFAF

AGGFF

AHCHY

AHEXY

AHGIF

AHKSF

AHKSY

AHWSF

AIBGY

AIBRF

AIQUY

AIRRF

AISSF

AJMPF

AJXGF

AKAOQ

AKBTY

AKZOY

ALBY

ALEAF

ALFVY

ALIAF

ALIF

ALIZF

ALLVF

ALMTF

ALPMY

ALSMY

ALVOF

ALYI

AMADY

AMAZ

AMBBY

AMIGY

AMKAF

AMKBF

AMKBY

AMLZF

AMMX

AMRQQ

AMXEF

ANEWF

ANGPY

ANPDF

ANPDY

ANSLY

ANTH

ANXGF

ANZBY

ANZLY

AOIFF

AOMFF

AOTVF

APELY

APHD

APMCF

AQARF

ARAFF

ARESF

ARGKF

ARKAY

ARNGF

ARREF

ARRRF

Stocks That Hit 52-Week Highs On Tuesday

<div>
	Entrega, an affiliate of PureTech Health (OTC:<a class="ticker" href="/stock/PTCHF#OTC">PTCHF</a>) focused on the oral delivery of complex molecules, such as peptides, that cannot currently be taken orally, is pleased to announce a research collaboration with Eli Lilly and Company (NYSE:<a class="ticker" href="/stock/LLY#NYSE">LLY</a>) (&quot;Lilly&quot;) toadvance Entrega&#39;s proprietary peptide delivery technology. Under the terms of the initial agreement, Entrega willreceive $5 million in equity and research funding from Lilly to investigate the application of Entrega&#39;s peptide delivery technology to certain Lilly products and therapeutic candidates. This initial agreement does not grant Lilly a developmentor commercialization license to the Entrega technology.</div>
<div>
	&nbsp;</div>
<div>
	&quot;We are excited to work with the innovative team atEntrega,&quot; said Divakar Ramakrishnan, Vice President, Drug Delivery and Device R&amp;D at Lilly. &quot;Their approach is novel and complements our broader efforts in oral macromolecule delivery.&quot;</div>
<div>
	&nbsp;</div>
<div>
	The vast majority of biologic drugs (including peptides, proteins and other macromolecules) are currently administered by injection, which can present challenges for healthcare delivery and compliance with treatment regimes. Oral administration thus represents an ideal delivery approach for this increasingly large class of therapies reshaping many areas of medicine. Entrega&#39;s technology platform is a unique approach to oral delivery which uses a proprietary, customizable hydrogel dosage form to control local fluid microenvironments in the GI tract to both enhance absorption and reduce the variability of drug exposure.</div>
<div>
	&nbsp;</div>
<div>
	&quot;Entrega has used a rigorous scientific approach to generate newinsights into one of the most challenging problems in drug delivery. Our proof-of-concept data demonstrates successful delivery of peptides in large animals,&quot; said Dr. Robert Langer, Chairman of Entrega&#39;s Scientific Advisory Board, non-executive Board member of PureTech Health and Institute Professor at the Massachusetts Institute of Technology (MIT). &quot;We are excited to work together with Lilly, who is an experienced collaborator in this important area of peptide delivery.&quot;</div>
 

Entrega to Receive $5M Investment from Lilly To Advance Proprietary Oral Delivery Technology for Peptides

Comments

PureTech Health

News

Latest news for PureTech Health (OTC:PTCHF) Stock

Tuesday, March 24, 2020

Tuesday, December 19, 2017

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga